Skip to main content

Hepatitis B Surface Antibody, Quantitative

CPT 86317
Synonyms
  • Anti-HBs
  • Antibody to Hepatitis B Surface Antigen
  • HBV

Test Details

Methodology

Immunochemiluminometric assay (ICMA)

Result Turnaround Time

1 - 2 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Use

This test is useful for quantitative (i.e., titer) evaluation of possible immunity in individuals who are at increased risk for exposure to hepatitis B (i.e., hemodialysis unit personnel, venipuncturists, etc.). This test can be used to evaluate the need for hepatitis B immune globulin after needlestick injury, to evaluate the need for hepatitis B vaccine and to follow immune status after hepatitis B vaccination.

Limitations

Presence of anti-HBs is not an absolute indicator of resolved hepatitis infection nor of protection from future infection. Since there are different serologic subtypes of hepatitis B virus, it is possible (and has been reported) for a patient to have antibody to one surface antigen type and to be acutely infected with a virus of a different subtype. Thus, a patient may have coexisting HBsAg and anti-HBs. Transfused individuals or hemophiliacs receiving plasma components may give false-positive tests for antibody to hepatitis B surface antigen.

References

Abara WE, Qaseem A, Schillie S, et al. Hepatitis B Vaccination, Screening, and Likage to Care: Best Practice Advice from American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017 Dec 5;167(11):794-804.29159414
Schillie S, Murphy TV, Sawyer M, et al. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management. MMWR Recomm Rep. 2013 Dec 20;62(RR-10):1-19.24352112
Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018 Jan 12;67(1):1-31.29939980
Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018 Apr;67(4):1560-1599.29405329
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.26042815

Specimen Requirements

Specimen

Serum or plasma

Volume

1 mL

Minimum Volume

0.5 mL (Note: This volume does not allow for repeat testing.)

Container

Red-top tube, gel-barrier tube, or lavender-top (EDTA) tube

Collection Instructions

If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.

Stability Requirements

Temperature

Period

Room temperature

14 days

Refrigerated

14 days

Frozen

14 days

Freeze/thaw cycles

Stable x3

Reference Range

• Immunity: >10.0 mIU/mL

Storage Instructions

Room temperature

Causes for Rejection

Non-EDTA plasma specimen; PST gel-barrier tube

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
006530 Hepatitis B Surf Ab Quant 16935-9 006531 Hepatitis B Surf Ab Quant mIU/mL 16935-9
Order Code006530
Order Code NameHepatitis B Surf Ab Quant
Order Loinc16935-9
Result Code006531
Result Code NameHepatitis B Surf Ab Quant
UofMmIU/mL
Result LOINC16935-9